Journal of Neurology Research, ISSN 1923-2845 print, 1923-2853 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Neurol Res and Elmer Press Inc
Journal website

Original Article

Volume 2, Number 5, October 2012, pages 189-197

Attenuated Laser Evoked Potentials in Sarcoidosis Patients in Clinical Remission


Figure 1.
Figure 1. Example of a Laser Evoked Potential (LEP) recordings in one representative healthy control (a), and below an example of an attenuated LEP in one representative sarcoidosis patient in clinical remission with complaints of burning pain (b). X-axis represents time in ms; Y-axis represents amplitude in µV. LEP was recorded at electrode Cz. Arrows indicate N2-latency and P2-latency in ms; horizontal lines indicate N2P2-amplitude (µV) over time (ms).
Figure 2.
Figure 2. Mean ± SEM N2P2-amplitude on laser intensity 1.0, 1.5 and 2.0 Watt.
Figure 3.
Figure 3. Mean ± SEM N2P2-amplitude per ms on laser intensity 1.0, 1.5 and 2.0 Watt.


Table 1. In- and Exclusion Criteria
Inclusion criteria:
Serum parameters (sIL-2R, ACE, Ca2+, CRP)normal
X-raynormal or 2 years or more stable
Lung functionnormal or 2 years or more stable, i.e.:
  VC or FEV1< 10% change
  DLco< 15% change
Previously involved organsno clinical signs of disease activity
Exclusion criteria:
sIL-2R: serum soluble interleukine-2 receptor, ACE: angiotensin converting enzyme, CRP: C-reactive protein, VC: vital capacity, FEV1: forced expired volume in the first second of expiration, DLco: diffusion capacity of the lung for carbon monoxide.
Lofgren’s syndromeat onset of sarcoidosis
Use of corticosteroids or other immunosuppressive drugsover the last 6 months
Use of analgesic medicationover the last 3 months
Antidepressive medicationover the last 3 months
Sleep apnea, narcolepsy or restless legs syndrome (by history)
Hb, thrombocytes, leucocytes, Na2+, K+, creatinine, GGT, AF, ASAT, ALAT, LDH, gluc, protein electrophoresis, TSH, ferritine, routine urine analysisabnormal
Age> 65 years


Table 2. Characteristics of Healthy Controls, Sarcoidosis Patients in Clinical Remission Split in a Group With Complaints of Burning Pain and a Group With no Complaints of Burning Pain
Healthy controlsSarcoidosis in clinical remissionP
with burning painno burning pain
Significant differences in bold. * Significant difference between healthy controls and patients with burning pain; and between healthy controls and patients without burning pain; # Sensory sum score was measured as follows: touch and pinprick sensation: 4: normal, 3: abnormal distal to wrist/ankle, 2: abnormal distal to half forearm/leg, 1: abnormal distal to knee/elbow, 0: abnormal distal to groin/axilla. Vibration sense: 128 Hz tuning fork perception on: 4: middle finger/hallux, 3: ulnar styloid/medial malleolus, 2: elbow/knee, 1: clavicle/iliac crest, 0: absent. Joint position sensation of middle finger/hallux: 2: normal, 1: diminished, 0: absent.
Report on pain in:00
  hands7 (2 males)
  feet5 (2 males)
  hands and feet5 (2 males)
Age in years (mean ± sd)34 ± 846 ± 947 ± 7< 0.001*
Time since diagnosis in years
(median (IQR))
7 (5 - 10)11 (6 - 18)0.002
Total number of affected organs (median (IQR))2 (1 - 3)2 (1 - 2)0.787
Former use of corticosteroids
  months of use (median (IQR))16 (0.5 - 30)16 (11 - 22)0.254
Sensory sum score #
  Total54.23 ± 3.455.33 ± 1.80.184
  touch and pinprick sensation
    Arm28.00 ± 027.95 ± 0.30.539
    Leg26.00 ± 3.926.98 ± 2.50.243
  vibration sense18.94 ± 2.119.64 ± 1.10.082
  Joint position sensation7.17 ± 1.47.73 ± 0.80.073
Atrophy Extensor Digitorum Brevis0.467
Achilles Reflex0.527